Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration.

The study examined how cetirizine, an antihistamine, behaves in the body of horses and its impact on their allergic reactions. The research found that regular doses of 0.2 to 0.4 mg/kg body weight every 12 hours can inhibit the formation of allergy-induced skin welts by up to 95% without noticeable side effects, making it a potentially useful treatment in equine medicine.

Understanding the Study

In order to provide a comprehensive explanation of the research paper, the content is divided into several key insights:

• Objective: The purpose of the study was to understand the pharmacokinetics (how the drug moves in the body) and pharmacodynamics (the effect of the drug on the body) of cetirizine in horses. Researchers specifically looked at how this antihistamine affected the formation of skin welts caused by histamine, a substance that the body produces during allergic reactions.
• Methodology: The study involved administering cetirizine orally to six healthy horses. Initially, doses of 0.2 mg/kg body weight were given every 12 hours for three cycles. After that, the dosage was increased to 0.4 mg/kg body weight for four cycles. Plasma concentrations were measured after each cycle, and the effectiveness of cetirizine in suppressing skin welts was evaluated.
• Results: After three cycles of 0.2mg/kg dosage, the study found a plasma concentration of cetirizine of 16 ng/mL and a 45% inhibition of welt formation. When the dosage was increased, the plasma concentration rose to 48 ng/mL, and welt formation inhibition rose to 68%. The elimination half-life of cetirizine from the body was about 5.8 hours.
• Pharmacokinetic/Pharmacodynamic Link: The researchers developed a model based on the results and found that the maximal inhibition of welt formation was roughly 95% and the concentration of cetirizine needed to achieve 50% of this maximum effect (EC50) was about 18 ng/mL.
• Conclusion: The study concluded that cetirizine in doses of 0.2-0.4 mg/kg body weight given at 12-hour intervals exhibited promising pharmacokinetic and pharmacodynamic properties. With no visible side effects, the drug could be useful as an antihistamine in equine medicine.

Implications of the Study

• This study provides notable information on the impact of cetirizine in horses and its potential viability as a histamine antagonist in equine medicine. The ability to reduce histamine-induced welts by up to 95% could significantly enhance the treatment and management of allergic conditions in horses.
• The research also gives a base dosage and administration frequency, providing a useful starting point for veterinarians prescribing cetirizine.
• Nevertheless, larger-scale studies with a broader range of horses would be beneficial to confirm these findings and to uncover any less common or long-term side effects.